Phreesia, Inc.

PHR
About the company

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada.

Country: United StatesPrice: $12.69Market Cap: $787.7M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

3 / 13

NEUTRAL / FAIL

Median fair value

$6.75

-46.8% vs price

Models with upside

2 / 17

Positive margin of safety

Strongest signal

9 of 12 pass — Buffett, Marks and Asness object

Key risk

Split decision: 13 FAIL · 3 NEUTRAL

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #1664 (Top 53.7%)NEUTRALFAILFAILFAILFAILFAILNEUTRALFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-466.5%-187.8%N/AN/AN/AN/A+52.3%-88.0%N/AN/A+68.2%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Annual history · FY 2025

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-07-31 · TTM ended 2026-07-31 vs 2025-07-31 · TTM ended 2026-07-31

Latest source filing: 2026-09-03

Score computed: 2026-11-14

TTM ended 2026-07-31

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Market data at 2026-11-01

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-07-31 · Balance sheet at 2026-07-31

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31 · Qualitative assessment

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Market data at 2026-11-01

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-07-31

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-07-31

Latest source filing: 2026-09-03

Score computed: 2026-11-14

TTM ended 2026-07-31 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-09-03

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage75% pass✓ 12✗ 3▾

    9 of 12 pass — Buffett, Marks and Asness object

    LT Debt vs Net Current AssetsLT Debt $1.1M vs NCA $109.7M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.18, IC: 1.2x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.18
    ✓Lynch< 0.33
    Cash - Long-term Debt$73.5M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change0.50% -> 0.40%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.76
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.18
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.18
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=1.2x, D/EBITDA=1.3x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.18
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.1787; #1606/4210 (top 38.1%)
    ✗AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Verdicts0% pass✗ 14▾

    Split decision: 13 FAIL · 3 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (4/7)✗GreenblattRank #1664•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)•AckmanNEUTRAL (6/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1481/2370 (Top 62.5%))✗NeffFAIL (2/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Profitability6% pass✓ 7✗ 28▾

    15 of 16 flag PHR's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)1/10 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/10 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-33.1%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-1.4% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$22.7M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 317.2x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE2.8%
    ✗Lynch> 15%
    EBIT / Enterprise Value1.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=1.6%, ROC=10.6%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets0.35%
    ✓PiotroskiROA > 0
    ROA Change YoY-15.07% -> 0.35% (delta: +15.42%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=11.87%, ROA=0.35%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY84.2% -> 85.2%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue0.5%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity2.8%
    ✗Dreman> 12%
    Margin of SafetyP/E=317.2x, P/B=2.3x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-25.3% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/9 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue2.5%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity2.8%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-38.3% (2023) -> -1.4% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 82.9% -> 85.2%, operating margin -38.3% -> -1.4%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+1.33%; #2902/6340 (top 45.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+61.65%; #444/3702 (top 12.0%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity+2.81%; #2692/5226 (top 51.5%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1671; #4038/5884 (top 68.6%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/9 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation8% pass✓ 1✗ 27▾

    12 of 13 flag PHR's valuation — Graham, Lynch, Greenblatt +9 more

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio2.3x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 317.2x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value1.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=1.6%, ROC=10.6%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS317.2x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)9.8x
    ✗Dreman< 8x
    Price / Book Value per Share2.3x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=317.2x, OE Yield=2.9%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=317.2x, FCF Yield=8.6%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=317.2x, P/B=2.3x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share11.4x
    ✓Ackman<= 25
    Price vs. Trailing Low151% of trailing low ($8.38)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+1.33%; #2902/6340 (top 45.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.4721; #2990/6449 (top 46.4%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS317.2x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share8.82x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-5.4%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.6447; #2307/5247 (top 44.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+10.25%; #734/4519 (top 16.2%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+37.79%; #851/6202 (top 13.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth13% pass✓ 4✗ 9▾

    7 of 8 flag PHR's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 317.2x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/9 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth17.8%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 82.9% -> 85.2%, operating margin -38.3% -> -1.4%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR26.4%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Efficiency13% pass✓ 1✗ 10▾

    7 of 8 flag PHR's efficiency — Graham, Buffett, Greenblatt +4 more

    Current Ratio1.76
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)-56.5%
    ✗Buffett> 10%
    ROIC - WACC-66.5%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)10.6%
    ✗Greenblatt> 25%
    Current Ratio Change YoY1.78 -> 1.53
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY1.08x -> 0.72x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities1.76
    ✓Dreman> 1.5
    Return on Invested Capital2.3%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-41.0%; FY2024: ROIC=-16.3%; FY2025: ROIC=-1.2%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC-1.2% (RR=100% x ROIC=-1.2%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -1.2%)
    ✗SleepROIC > 12% in a majority of years
  • Valuation models40% pass✓ 2✗ 3▾

    Models split on PHR at $12.69 — fair values range $2.24–$39.95

    Graham fair value$2.24
    ✗Graham-466.5% margin vs $12.69
    Buffett fair value$4.41
    ✗Buffett-187.8% margin vs $12.69
    Munger fair value$26.60
    ✓Munger+52.3% margin vs $12.69
    Pabrai fair value$6.75
    ✗Pabrai-88.0% margin vs $12.69
    Ackman fair value$39.95
    ✓Ackman+68.2% margin vs $12.69
  • Cash Flow50% pass✓ 7✗ 5▾

    5 of 10 pass — Dreman, Pabrai, Marks +2 more object

    Free Cash Flow Proxy$22.7M
    ✓BuffettPositive and growing
    FCF Positive and Growing$80.7M
    ✓LynchPositive and growing
    Operating Cash Flow$78.8M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=11.87%, ROA=0.35%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)9.8x
    ✗Dreman< 8x
    P/E or FCF YieldP/E=317.2x, FCF Yield=8.6%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive2/9 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap10.5%
    ✓Ackman>= 4%
    Price / FCF per Share11.4x
    ✓Ackman<= 25
    Positive Operating Cash Flow frequency4/9 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$80.7M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+10.25%; #734/4519 (top 16.2%)
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Business Services
Size: Small Cap($787.7M)
Revenue: $480.6M+14.5% YoY
Net Income: $2.3M+103.9% YoY

Financial Snapshot

Operating Margin-1.4%
Return on Equity0.7%
Debt / Equity0.30
Current Ratio1.53
EPS (Diluted)$0.04
Shares Retired−3.3% / −7.7% 2y

Shareholder Return

Fiscal 2025

Issued 3.3% of shares last year, 7.7% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-07-31

2025-08-01 – 2026-07-31

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

Q2 FY 2027

2026-05-01 – 2026-07-31

Sources
Q1 FY 2027

2026-02-01 – 2026-04-30

Sources
FY 2025
Sources
  • 10-K · 2026-03-31
FY 2024
Sources
  • 10-K · 2025-03-13
FY 2023
Sources
  • 10-K · 2024-03-15
FY 2022
Sources
  • 10-K · 2024-03-15
FY 2021
Sources
  • 10-K · 2022-03-31
Market Cap$787.7Mcurrent----$815.4Mest.$1.7Best.$1.4Best.$2.0Best.$1.6Best.
Revenue$507.8M↑13%$129.5M↑10%$130.9M↑13%$480.6M↑14%$419.8M↑18%$356.3M↑27%$280.9M↑32%$213.2M
Operating Income$12.5M↑148%$7.6M↑605%$6.7M↑305%-$6.6M↑89%-$58.1M↑57%-$136.5M↑23%-$176.6M↓51%-$116.8M
Net Income$10.4M↑143%$1.9M↑193%$3.0M↑176%$2.3M↑104%-$58.5M↑57%-$136.9M↑22%-$176.1M↓49%-$118.2M
EPS (Diluted)--$0.03↑200%$0.05↑171%$0.04↑104%$-1.02↑59%$-2.51↑25%$-3.36↓42%$-2.37
Gross Margin———85.2%↑1%84.2%↑2%82.9%↑5%79.0%↓1%80.0%
Operating Margin2.5%↑142%5.9%↑557%5.2%↑282%-1.4%↑90%-13.8%↑64%-38.3%↑39%-62.9%↓15%-54.8%
ROE2.8%↑135%——0.7%↑103%-22.1%↑59%-54.4%↑11%-61.2%↓116%-28.3%
Total Debt$66.4M↑469%$66.4M↑469%$90.6M↑524%$100.1M↑518%$16.2M↑41%$11.5M↑45%$7.9M↓40%$13.2M
Shareholders' Equity$371.9M↑25%$371.9M↑25%$359.1M↑27%$337.2M↑27%$264.8M↑5%$251.4M↓13%$287.8M↓31%$417.3M
Current Ratio1.76↓17%1.76↓17%1.76↓10%1.53↓14%1.781.78↓46%3.32↓41%5.65
Debt / Equity0.18↑356%0.18↑356%0.25↑391%0.30↑385%0.06↑34%0.05↑66%0.03↓14%0.03
Operating Cash Flow$91.4M↑77%$18.3M↑24%$23.9M↑61%$78.8M↑143%$32.4M↑200%-$32.4M↑64%-$90.1M↓21%-$74.7M
Free Cash Flow$80.7M↑88%$17.8M↑36%$19.6M↑73%$67.7M↑186%$23.7M↑162%-$38.2M↑60%-$94.9M↓2%-$93.1M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Business Services

PHR vs Peers — Financial Grading

Revenue$480.6MBottom 25%
Net Income$2.3MMedian
ROE0.7%Bottom 25%
D/E0.30Top 25%
Op. Margin-1.4%Bottom 25%
Curr. Ratio1.53Median
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
AUTOMATIC DATA PROCESSING INCADP$122.3B$309.93$21.9B$4.4B73.2%0.8224.2%1.054/95/93/70/3F-Score 65/11
ELECTRONIC ARTS INC.EA$52.9B$209.70$7.5B$887.0M13.1%0.2215.4%1.051/94/94/70/3F-Score 66/11
Rubrik, Inc.RBRK$22.6B$109.88$1.3B$348.8M67.1%—-26.2%1.691/90/92/70/3F-Score 62/11
AECOMACM$9.1B$70.50$16.1B$561.8M22.5%1.096.4%1.141/93/93/71/3F-Score 82/11
COMMVAULT SYSTEMS INCCVLT$6.2B$152.07$1.2B$70.7M942.8%—6.3%1.951/92/94/70/3F-Score 66/11
WPP plcWPP$6.0B$27.79$18.2B$289.5M-8.5%1.942.8%0.891/92/91/70/3F-Score 32/11
VARONIS SYSTEMS INCVRNS$5.6B$48.94$623.5M$129.3M-21.6%0.76-23.5%1.971/90/91/70/3F-Score 51/11
ROBERT HALF INC.RHI$4.3B$42.00$5.4B$133.0M10.4%—1.4%1.532/95/91/70/3F-Score 52/11